Mark Awadalla
About Mark Awadalla
Vice President of Clinical Operations at Capricor
Mark Awadalla joined Capricor in 2023 and currently holds the position of Vice President of Clinical Operations. In this role, he brings extensive experience and expertise in cell therapy clinical trials across multiple therapeutic areas. His responsibilities include overseeing various clinical operations and ensuring the successful execution of clinical trials.
Expertise in Cell Therapy Clinical Trials
Mark specializes in cell therapy clinical trials, with experience spanning diverse therapeutic areas such as oncology, inflammation, degenerative, and rare diseases. His comprehensive knowledge and hands-on experience have made him a key player in the advancement of cell therapy research and clinical applications.
Leadership Roles at Celularity Inc.
Before joining Capricor, Mark Awadalla served as Vice President of Research and Development and Head of Clinical Operations at Celularity Inc. During his tenure, he oversaw the clinical portfolio, designing and executing multiple clinical trials. His leadership and strategic planning significantly contributed to the progress of clinical studies and research initiatives at the company.
Clinical Operations at Mustang Bio
At Mustang Bio, Mark led the clinical operations team, successfully clearing Investigational New Drug (IND) applications and initiating the company's first clinical trial with an autologous cell therapy product. His role was crucial in advancing the company's clinical development efforts.
Global Clinical Operations at Celgene
Mark Awadalla held roles of increasing responsibility in global clinical operations at Celgene. He played an integral role in the execution, management, and submission of global clinical trials, which culminated in the New Drug Application (NDA) approval of Otezla®. His contributions were pivotal to the regulatory success and market introduction of the product.
Educational Background
Mark Awadalla received his Bachelor of Science in Biochemistry/Molecular Biology from the Richard Stockton University of New Jersey. His academic background provided a strong foundation for his career in clinical operations and research development.